Literature DB >> 11157741

The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.

R Stoll1, C Renner, M Zweckstetter, M Brüggert, D Ambrosius, S Palme, R A Engh, M Golob, I Breibach, R Buettner, W Voelter, T A Holak, A K Bosserhoff.   

Abstract

Melanoma inhibitory activity (MIA) protein is a clinically valuable marker in patients with malignant melanoma, as enhanced values diagnose metastatic melanoma stages III and IV. Here we show that the recombinant human MIA adopts an SH3 domain-like fold in solution, with two perpendicular, antiparallel, three- and five-stranded beta-sheets. In contrast to known structures with the SH3 domain fold, MIA is a single-domain protein, and contains an additional antiparallel beta-sheet and two disulfide bonds. MIA is also the first extracellular protein found to have the SH3 domain-like fold. Furthermore, we show that MIA interacts with fibronectin and that the peptide ligands identified for MIA exhibit a matching sequence to type III human fibronectin repeats, especially to FN14, which is close to an integrin alpha4beta1 binding site. The present study, therefore, may explain the role of MIA in metastasis in vivo, and supports a model in which the binding of human MIA to type III repeats of fibronectin competes with integrin binding, thus detaching cells from the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157741      PMCID: PMC133488          DOI: 10.1093/emboj/20.3.340

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

1.  Crystal structure of a heparin- and integrin-binding segment of human fibronectin.

Authors:  A Sharma; J A Askari; M J Humphries; E Y Jones; D I Stuart
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

2.  Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein.

Authors:  R Stoll; C Renner; D Ambrosius; M Golob; W Voelter; R Buettner; A K Bosserhoff; T A Holak
Journal:  J Biomol NMR       Date:  2000-05       Impact factor: 2.835

Review 3.  Practical introduction to theory and implementation of multinuclear, multidimensional nuclear magnetic resonance experiments.

Authors:  A S Edison; F Abildgaard; W M Westler; E S Mooberry; J L Markley
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  Structural features of fibronectin synthetic peptide FN-C/H II, responsible for cell adhesion, neurite extension, and heparan sulfate binding.

Authors:  S L Drake; J Varnum; K H Mayo; P C Letourneau; L T Furcht; J B McCarthy
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

5.  Overcoming the overlap problem in the assignment of 1H NMR spectra of larger proteins by use of three-dimensional heteronuclear 1H-15N Hartmann-Hahn-multiple quantum coherence and nuclear Overhauser-multiple quantum coherence spectroscopy: application to interleukin 1 beta.

Authors:  D Marion; P C Driscoll; L E Kay; P T Wingfield; A Bax; A M Gronenborn; G M Clore
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

6.  MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis.

Authors:  U Müller-Ladner; A K Bosserhoff; K Dreher; R Hein; M Neidhart; S Gay; J Schölmerich; R Buettner; B Lang
Journal:  Rheumatology (Oxford)       Date:  1999-02       Impact factor: 7.580

7.  SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.

Authors:  C A Koch; D Anderson; M F Moran; C Ellis; T Pawson
Journal:  Science       Date:  1991-05-03       Impact factor: 47.728

8.  Determination of the disulphide bonding pattern in proteins by local and global analysis of nuclear magnetic resonance data. Application to flavoridin.

Authors:  W Klaus; C Broger; P Gerber; H Senn
Journal:  J Mol Biol       Date:  1993-08-05       Impact factor: 5.469

9.  Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA.

Authors:  A Blesch; A K Bosserhoff; R Apfel; C Behl; B Hessdoerfer; A Schmitt; P Jachimczak; F Lottspeich; R Buettner; U Bogdahn
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

10.  Evidence that binding to the carboxyl-terminal heparin-binding domain (Hep II) dominates the interaction between plasma fibronectin and heparin.

Authors:  M J Benecky; C G Kolvenbach; D L Amrani; M W Mosesson
Journal:  Biochemistry       Date:  1988-09-20       Impact factor: 3.162

View more
  17 in total

1.  Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites.

Authors:  Jeffrey L Pitman; David J Bonnet; Linda K Curtiss; Nicholas Gekakis
Journal:  J Lipid Res       Date:  2011-08-01       Impact factor: 5.922

2.  Solution structure and dynamics of melanoma inhibitory activity protein.

Authors:  Julie C Lougheed; Peter J Domaille; Tracy M Handel
Journal:  J Biomol NMR       Date:  2002-03       Impact factor: 2.835

3.  Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains.

Authors:  Raphael Stoll; Christian Renner; Reinhard Buettner; Wolfgang Voelter; Anja-Katrin Bosserhoff; Tad A Holak
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

4.  Ultrastructural cartilage abnormalities in MIA/CD-RAP-deficient mice.

Authors:  Markus Moser; Anja-Katrin Bosserhoff; Ernst B Hunziker; Linda Sandell; Reinhard Fässler; Reinhard Buettner
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

5.  Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

Authors:  King Tuo Yip; Xueyin Zhong; Nadia Seibel; Oliver Arnolds; Miriam Schöpel; Raphael Stoll
Journal:  Biointerphases       Date:  2017-05-31       Impact factor: 2.456

6.  Misexpression of MIA disrupts lung morphogenesis and causes neonatal death.

Authors:  Sui Lin; Machiko Ikegami; Yan Xu; Anja-Katrin Bosserhoff; Alvin M Malkinson; John M Shannon
Journal:  Dev Biol       Date:  2008-02-15       Impact factor: 3.582

7.  A genome-wide RNA interference screen identifies two novel components of the metazoan secretory pathway.

Authors:  Franz Wendler; Alison K Gillingham; Rita Sinka; Cláudia Rosa-Ferreira; David E Gordon; Xavier Franch-Marro; Andrew A Peden; Jean-Paul Vincent; Sean Munro
Journal:  EMBO J       Date:  2009-11-26       Impact factor: 11.598

8.  Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy.

Authors:  Jan Senderek; Carsten Bergmann; Claudia Stendel; Jutta Kirfel; Nathalie Verpoorten; Peter De Jonghe; Vincent Timmerman; Roman Chrast; Mark H G Verheijen; Greg Lemke; Esra Battaloglu; Yesim Parman; Sevim Erdem; Ersin Tan; Haluk Topaloglu; Andreas Hahn; Wolfgang Müller-Felber; Nicolò Rizzuto; Gian Maria Fabrizi; Manfred Stuhrmann; Sabine Rudnik-Schöneborn; Stephan Züchner; J Michael Schröder; Eckhard Buchheim; Volker Straub; Jörg Klepper; Kathrin Huehne; Bernd Rautenstrauss; Reinhard Büttner; Eva Nelis; Klaus Zerres
Journal:  Am J Hum Genet       Date:  2003-10-21       Impact factor: 11.025

9.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

10.  Modulation of cartilage differentiation by melanoma inhibiting activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP).

Authors:  Thomas Schubert; Jacqueline Schlegel; Rainer Schmid; Alfred Opolka; Susanne Grassel; Martin Humphries; Anja-Katrin Bosserhoff
Journal:  Exp Mol Med       Date:  2010-03-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.